Form 4: Alon Lazarus Acquires 17,500 Stock Options in Werewolf Therapeutics

Director Alon Lazarus acquired 17,500 stock options in Werewolf Therapeutics on May 24, 2024, at an exercise price of $4.88.

Summary

• Alon Lazarus, a director of Werewolf Therapeutics, acquired 17,500 stock options on May 24, 2024.
• The exercise price of the options is $4.88.
• The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant date, contingent upon continued service as a director.
• The options expire on May 23, 2034.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports the acquisition of stock options by a director, which is a routine transaction.

Future Outlook

The vesting of the options is contingent upon the reporting person's continued service as a director, suggesting an ongoing commitment to the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors, offering insights into their confidence in the company's future prospects.

Stakeholder Impact

• The acquisition of stock options by a director can signal confidence in the company's future performance to shareholders.

Key Dates